Results 21 to 30 of about 16,333 (257)
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals [PDF]
Journal of Clinical and Translational Hepatology, 2016 Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of ...
Rice, Donald P. +3 more
openaire +2 more sources
Pharmaceuticals, 2023 Combining antiviral drugs with different mechanisms of action can help prevent the development of resistance by attacking the infectious agent through multiple pathways.
Liliana Betancur-Galvis +4 more
doaj +1 more source
Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
Nefrología (English Edition), 2017 Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection.
Soraya Abad +9 more
doaj +1 more source
Chronic Hepatitis C Treatment with New Antiviral Agents
Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018 Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed.
Özlem KANDEMİR
doaj +1 more source
Broad-Spectrum Antivirals Derived from Natural Products
Viruses, 2023 Scientific advances have led to the development and production of numerous vaccines and antiviral drugs, but viruses, including re-emerging and emerging viruses, such as SARS-CoV-2, remain a major threat to human health.
Wen-Jun Tian, Xiao-Jia Wang
doaj +1 more source
Annals of Hepatology, 2019 Introduction and aim: Recurrent HCV infection after liver transplant (LT) has a negative impact on graft and patient survival. The aim of this study is to describe the efficacy and safety of sofosbuvir (SOF-based) regimens in the treatment of recurrent ...
Alexandre Araujo +5 more
doaj +1 more source
Hepatitis C at presentation in a newly diagnosed infant with B Acute Lymphoblastic Leukemia
Pediatric Hematology Oncology Journal, 2018 We report the unique case of a nine-month old patient diagnosed with B- Cell Acute Lymphoblastic Leukemia also positive for Hepatitis C virus, genotype 3 and a high viral load.
Qurratulain Shahood Ahmed +3 more
doaj +1 more source
Mortality associated with the treatment of HCV with direct-acting antivirals [PDF]
Gut, 2017 We read with interest the study by Welzel et al 1 confirming the high efficacy of oral direct-acting antiviral agents (DAAs) for the treatment of chronic HCV infection.2 Results about safety are less clear, since in these patients who have a high risk of hepatic decompensation or death within 12 months, the rate of death was 7.8% during treatment and ...
Anne, Laurain +5 more
openaire +2 more sources
Self-reported experience in patients treated with Hepatitis C direct acting antivirals [PDF]
Farmacia Hospitalaria, 2016 Background and objective: To learn about and analyze the self-reported treatment experience of HCV patients who started treatment with direct acting antivirals agents (DAA), at a real-time, proactive and integrated into the pharmaceutical care healthcare
Irene Cañamares Orbis +5 more
doaj +1 more source
International Journal of Infectious Diseases, 2021 Objectives: Due to limited hepatitis C virus (HCV) sequence availability from patients in Russia, the relationship between subtypes and baseline resistance-associated substitutions (RAS) to direct antiretroviral treatment outcome is not fully understood.
Vasily Isakov +14 more
doaj +1 more source